Lykan plans 90 capacity expansion to cell therapy manufacturing

摘要

Lykan Bioscience, a contract development and manufacturing organisation focused on cell-based therapies, has announced plans to expand its purpose-built facility in Hopkinton, MA. Seven ISO Class 7 cGMP suites will be added to the existing facility with capabilities for both autologous and allogeneic production. The new suites will meet FDA regulatory guidelines for US clinical and commercial production; three of the suites will also meet EMEA guidelines for EU commercial production. The expansion is expected to be commissioned and operational for partner programmes by Q4 2022.